Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension

Roberto Fogari, Amedeo Mugellini

Research output: Contribution to journalArticle

Abstract

The antihypertensive efficacy and tolerability of combination therapy with candesartan cilexetil, 16 mg plus hydrochlorothiazide (CC/HCTZ), 12.5 mg was compared with that of amlodipine, in a multicentre, double-blind, randomised, parallel-group study in patients with mild-to-moderate essential hypertension inadequately controlled by monotherapy. After a two week run-in period on existing therapy, patients with a sitting diastolic blood pressure (DBP) of 90-110 mmHg and a sitting systolic blood pressure (SBP) ≤ 180 mmHg were switched to either CC/HCTZ (n=101) or amlodipine (n=102), once-daily by mouth. After eight weeks of treatment, both regimens reduced mean trough blood pressure (BP) by a similar amount: mean sitting SBP/DBP reductions were -15.4/-11.9 mmHg for CC/HCTZ, and -15.7/-12.0 mmHg for amlodipine (group differences, p=0.835/0.963). The BP of 84.2% of patients on CC/HCTZ and 84.5% on amlodipine was controlled (sitting DBP <90 mmHg and sitting SBP <140 mmHg) (P=1.00). Six (5.9%) patients on CC/HCTZ and 18 (17.6%) on amlodipine discontinued treatment, including one (1%) and 13 (12.7%) owing to adverse events (p

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalJRAAS - Journal of the Renin-Angiotensin-Aldosterone System
Volume8
Issue number3
DOIs
Publication statusPublished - Sep 2007

Keywords

  • Amlodipine
  • Candesartan
  • Hydrochlorothiazide
  • Hypertension

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine

Fingerprint Dive into the research topics of 'Efficacy and tolerability of candesartan cilexetil/hydrochlorothiazide and amlodipine in patients with poorly controlled mild-to-moderate essential hypertension'. Together they form a unique fingerprint.

  • Cite this